Treatment	O
of	O
transplanted	O
CT26	B-Cancer
tumour	I-Cancer
with	O
dendritic	B-Cell
cell	I-Cell
vaccine	O
in	O
combination	O
with	O
blockade	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
and	O
CTLA	O
-	O
4	O
.	O

We	O
investigated	O
the	O
anti	O
CT26	B-Cancer
tumour	I-Cancer
effect	O
of	O
dendritic	B-Cell
cell	I-Cell
based	O
vaccination	O
with	O
the	O
MuLV	O
gp70	O
envelope	B-Cellular_component
protein	O
-	O
derived	O
peptides	O
AH1	O
and	O
p320	O
-	O
333	O
.	O

Vaccination	O
lead	O
to	O
generation	O
of	O
AH1	O
specific	O
cytotoxic	B-Cell
lymphocytes	I-Cell
(	O
CTL	B-Cell
)	O
and	O
some	O
decrease	O
in	O
tumour	B-Cancer
growth	O
of	O
simultaneously	O
inoculated	O
CT26	B-Cell
cells	I-Cell
.	O

After	O
combination	O
with	O
an	O
antibody	O
against	O
VEGF	O
receptor	O
2	O
(	O
DC101	O
)	O
,	O
a	O
significant	O
increase	O
in	O
survival	O
of	O
the	O
tumour	B-Cell
cell	I-Cell
recipients	O
was	O
observed	O
.	O

Also	O
,	O
monotherapy	O
with	O
an	O
antibody	O
against	O
CTLA	O
-	O
4	O
(	O
9H10	O
)	O
,	O
led	O
to	O
approximately	O
100	O
%	O
survival	O
of	O
tumour	B-Cell
cell	I-Cell
recipients	O
.	O

However	O
,	O
effective	O
treatment	O
of	O
mice	O
with	O
already	O
established	O
tumours	B-Cancer
was	O
only	O
obtained	O
after	O
combination	O
of	O
vaccination	O
,	O
DC101	O
and	O
9H10	O
treatment	O
in	O
which	O
setting	O
80	O
%	O
of	O
the	O
mice	O
rejected	O
their	O
tumours	B-Cancer
.	O

